Scientists use swarms of nanobots to precisely target cancer
Being able to deliver drugs in situ within the human body precisely to the areas where they can do the most good will help doctors treat patients better and patients recover faster.
Key takeaways
- Researchers from Polytechnique Montréal, Université de Montréal and McGill University have just achieved a spectacular breakthrough in cancer research.
- Hypoxic zones are known to be resistant to most therapies, including radiotherapy.
- Bacteria with compass To move around, bacteria used by Professor Martel’s team rely on two natural systems.
Cite or link to this article
Griffin, M. (2016) 'Scientists use swarms of nanobots to precisely target cancer', 311 Institute, 21 August. Available at: https://www.311institute.com/scientists-use-swarms-of-nanobots-to-precisely-target-cancer/ (Accessed: 1 October 2026).
Researchers from Polytechnique Montréal, Université de Montréal and McGill University have just achieved a spectacular breakthrough in cancer research. They have developed new nanorobotic agents capable of navigating through the bloodstream to administer a drug with precision by specifically targeting the active cancerous cells of tumours. This way of injecting medication ensures the optimal targeting of a tumour and avoids jeopardizing the integrity of organs and surrounding healthy tissues. As a result, the drug dosage that is highly toxic for the human organism could be significantly reduced.
This scientific breakthrough has just been published in the prestigious journal Nature Nanotechnology in an article titled“Magneto-aerotactic bacteria deliver drug-containing nanoliposomes to tumour hypoxic regions” and the article notes the results of the research done on mice, which were successfully administered nanorobotic agents into tumours.
“These legions of nanorobotic agents were actually composed of more than 100 million flagellated bacteria, and therefore self-propelled, and loaded with drugs that moved by taking the most direct path between the drug’s injection point and the area of the body to cure,” explains professor Sylvain Martel, holder of the Canada Research Chair in Medical Nanorobotics and director of the Polytechnique Montréal Nanorobotics Laboratory, who heads the research team’s work.
“The drug’s propelling force was enough to travel efficiently and enter deep inside the tumours.”
When they enter a tumour, the nanorobotic agents can detect in a wholly autonomous fashion the oxygen-depleted tumour areas, known as hypoxic zones, and deliver the drug to them. This hypoxic zone is created by the substantial consumption of oxygen by rapidly proliferative tumour cells. Hypoxic zones are known to be resistant to most therapies, including radiotherapy.
But gaining access to tumours by taking paths as minute as a red blood cell and crossing complex physiological micro-environments does not come without challenges. So Professor Martel and his team used nanotechnology to do it.
Bacteria with compass
To move around, bacteria used by Professor Martel’s team rely on two natural systems. A kind of compass created by the synthesis of a chain of magnetic nanoparticles allows them to move in the direction of a magnetic field, while a sensor measuring oxygen concentration enables them to reach and remain in the tumour’s active regions. By harnessing these two transportation systems and by exposing the bacteria to a computer-controlled magnetic field, researchers showed that these bacteria could perfectly replicate artificial nanorobots of the future designed for this kind of task.
“This innovative use of nanotransporters will have an impact not only on creating more advanced engineering concepts and original intervention methods, but it also throws the door wide open to the synthesis of new vehicles for therapeutic, imaging and diagnostic agents,” professor Martel adds.
“Chemotherapy, which is so toxic for the entire human body, could make use of these natural nanorobots to move drugs directly to the targeted area, eliminating the harmful side effects while also boosting its therapeutic effectiveness.”
The work by professor Martel was supported by the Québec consortium for drug discovery (CQDM), the Canada Research Chairs, the Natural Sciences and Engineering Research Council of Canada (NSERC), the Research Chair in Nanorobotics of Polytechnique Montréal, Mitacs, the Canada Foundation for Innovation (CFI) and the National Institutes of Health (NIH). Montréal’s Jewish General Hospital, the McGill University Health Centre (MUHC), the Institute for Research in Immunology and Cancer (IRIC), and the Rosalind and Morris Goodman Cancer Research Centre also took part in this research work.
What this means for your organisation
The evidence is still in mice.
The results come from work on mice. Each group of nanorobotic agents held more than 100 million bacteria. Treat this as an early signal, not a product. Engineered red blood cells, which also carry medicine around the body, are rated Watch, with a first product around 2032.
Hard to reach tumour zones are the target.
Low-oxygen zones in tumours resist most therapies, including radiotherapy. The bacteria find these zones on their own, using a magnetic compass and an oxygen sensor. Radioligand cancer therapy, which links a radioactive atom to a molecule that finds tumour cells, is already at TRL 9. Precise targeting is becoming the common aim.
Lower doses could change the care model.
The team says a highly toxic drug dose could be reduced, and that chemotherapy could use these natural nanorobots to reach the target area. Lymphatic-targeted drug delivery points the same way, sending treatments straight to one part of the body. 311 rates it Watch, with wide use around 2042.
Three questions for your next leadership meeting
- Which of our cancer treatments depend on high doses that harm healthy tissue?
- Who is tracking targeted delivery research that is still at the mouse stage?
- What would we need to change if lower doses became possible?
The trends and technologies behind this story
From the 311 Starburst, the 311 Strategic Intelligence Unit’s map of the technologies and trends shaping the next 50 years.
Analysis by the 311 Strategic Intelligence Unit, from Matthew Griffin’s article and 311 data. First published on Fanatical Futurist.
FAQ
Why does this matter?
Being able to deliver drugs in situ within the human body precisely to the areas where they can do the most good will help doctors treat patients better and patients recover faster.

About the author
Matthew Griffin Founder, 311 Institute
Matthew Griffin is a multi-award winning Futurist and expert in Disruption and Innovation, Geopolitics, Leadership, and Technology, who NASA have described as a "walking encyclopaedia of the future" and a "futurist Polymath."
Read full bio
Matthew Griffin is a multi-award winning Futurist and expert in Disruption and Innovation, Geopolitics, Leadership, and Technology, who NASA have described as a "walking encyclopaedia of the future" and a "futurist Polymath." 17-time best selling author of the "Codex of the Future" series, Matthew is the Founder and Futurist in Chief of the 311 Institute, a global Futures and Deep Futures advisory firm working with royal households, world leaders, G7, G20, and G77 governments, NGOs, and multi-national mid and mega cap firms to help them explore, shape, and lead the next 50 years of business and society.
An award-winning YouTube creator with over a million followers, with an unrivalled global reach and impact, Matthew is a highly sought-after international keynote speaker, lecturer, and mentor who collaborates with global leaders through the United Nations Alliance of Civilizations (UNAOC) and United Nations General Assembly (UNGA) to shape pivotal initiatives such as the UN’s AI for Humanity program, the United Nations Conference of the Parties (UN COP), and the World Economic Forum in Davos.
As the former Global Head of Cloud, National Security, and Enterprise Sales for companies including Atos, Dell-EMC, and IBM, Matthew has a proven track record of building multi-billion dollar business units and turning failing divisions into market leaders. His ability to identify, analyse, and communicate the implications of hundreds of emerging technologies and trends is unparalleled, and his insights are trusted by many of the world’s most respected organisations, including ABB, Accenture, Adidas, AON, ARM, BCG, Centrica, Citi, Coca-Cola, Dentons, Deloitte, Dow Jones, EY, Google, KPMG, Lego, Legal & General, LinkedIn, Microsoft, PepsiCo, Qualcomm, RWE, Samsung, Siemens AG and Siemens Energy, T-Mobile, UBS, VISA, Walmart, Workday, Worldpay and many others.
Regularly featured in the global media including the AP, BBC, Bloomberg, CNBC, Discovery, Forbes, Khaleej Times, Telegraph, TIME, ViacomCBS, WIRED, and the WSJ, Matthews mission is to help organisations create a fair and sustainable future whose benefits are shared by everyone irrespective of their ability, background, or circumstances.
What future do you need to see?
Choose one to get started on biotech and enhanced humans and the future of your organisation.
Source: first published by the 311 Institute on 21 August 2016. Cite as: Griffin, M. (2016). Scientists use swarms of nanobots to precisely target cancer. 311 Institute. https://www.311institute.com/scientists-use-swarms-of-nanobots-to-precisely-target-cancer/
You are welcome to quote this article with credit and a link to the original.